Premature thelarche in an 8-year-old girl following prolonged use of risperidone

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 4, 2014, Pages 228-230

  White, Presenters Anne L ^a   Singh, Rajinderpal ^a   Rais, Theodor ^a   Coffey, Barbara J ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; METHYLPHENIDATE; RISPERIDONE; NEUROLEPTIC AGENT;

AGGRESSION; ALCOHOLISM; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; BIPOLAR DISORDER; CASE REPORT; CAUCASIAN; CHILD; CONCENTRATION LOSS; DRUG DEPENDENCE; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; INCREASED APPETITE; INSOMNIA; MENTAL HEALTH; MOOD CHANGE; PRECOCIOUS PUBERTY; PSYCHOSIS; PSYCHOTIC DISORDER NOT OTHERWISE SPECIFIED; SCHIZOPHRENIA; SCHOOL CHILD; SLEEP DISORDER; TREATMENT DURATION; VISUAL HALLUCINATION; BREAST; CHEMICALLY INDUCED; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; PSYCHOTIC DISORDERS; TIME;

ANTIPSYCHOTIC AGENTS; BREAST; CHILD; FEMALE; HUMANS; PSYCHOTIC DISORDERS; PUBERTY, PRECOCIOUS; RISPERIDONE; TIME FACTORS;

EID: 84901272728     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2014.2442     Document Type: Article

References (15)

1. Cabrera SM, Bright GM, Frane JW, Blethen SL, Lee PA: Age of thelarche and menarche in contemporary U.S. females: A cross-sectional analysis. J Pediatr Endocrinol Metab 27: 47-51, 2014
2. Caccia S: Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs 15:217-233, 2013
3. Correll CU, Leucht S, Kane JM: Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry, 20:195-201, 2008
4. Dunbar F, Kusumakar V, Daneman D, Schulz M: Growth and sexual maturation during long-Term treatment with risperidone. Am J Psychiatry 161:918-920, 2004
5. Greenspan SL, Oppenheim DS, Klibanski A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526-531, 1989
6. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R: Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: Response to medical therapy. Clin Endocrinol (Oxf) 30:131-140, 1989
7. Kawano Y, Kamihigashi S, Nakamura S, Miyakawa I: Delayed puberty associated with hyperprolactinemia caused by a pituitary microadenoma. Arch Gynecol Obstet 264:90-92, 2000
8. Patton ML, Woolf PD: Hyperprolactinemia and delayed puberty: A report of three cases and their response to therapy. Pediatrics 71:572-575, 1983
9. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Long-Term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006
10. Roke Y, van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19:403-414, 2009
11. Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN: Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder treated with risperidone. J Child Adolesc Psychopharmacol 22:432-439, 2012
12. Sack J, Friedman E, Tadmor R, Sahar A, Katznelson D: Growth and puberty arrest due to prolactinoma. Acta Paediatr Scand 73:863-867, 1984
13. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004
14. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. Presented in part as a poster presentation at the 6th International Bipolar Disorders Conference, Pittsburgh, Pennsylvania, June 16-18, 2005
15. Toren P, Ratner S, Laor N, Weizman A: Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 27:1135-1156, 2004